The FDA submission is for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, based on three phase 3 studies showing that elinzanetant significantly reduced ...

May 13, 2025 — Researchers have conducted a clinical study to show how a woman's genetic profile provides information on which hormone treatment is most effective for in vitro fertilization (IVF ...